RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

PURPOSE The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS Patients with SCLC and progression on or after first-line platinum-based chemotherapy were randomly assigned (1:1) to intravenous (IV) l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Spigel, David R, Dowlati, Afshin, Chen, Yuanbin, Navarro, Alejandro, Stojanovic, Goran, Andric, Zoran G, Wu, Yi-long, Rudin, Charles M, Kobziev, Oleh, Kurochkin, Andriy, Semegen, Yuriy, Sinielnikov, Ivan, Tarasenko, Tetiana, Trukhin, Dmytro, Carlisle, Jennifer, Carr, Laurie, Chaudhry, Arvind, Chen, Huanyu, Chen, Hongbin, Edenfield, William, Jotte, Robert, Lingerfelt, Brian, Mccune, Steven, Zhang, Li, Nagajothi, Nagaprasad, Rubin, Peter, Scilla, Katherine, Weise, Amy, Zuniga, Richard, On Behalf Of The Resilient Trial Investigators, Yeung, Stanley, Benzaghou, Fawzi, Paz-Ares, Luis, Bunn, Paul A, Clingan, Philip, Hayes, Theresa, Underhill, Craig, Demey, Wim, Forget, Frederic, Lambrechts, Marc, Nackaerts, Kristiaan, Azambuja, Alan Arrieira, Mourao Dias, Josiane, Santos, Victor, Cezar Uchoa Junior, Bruno, Alves, Gustavo Vasconcelos, De Melo Sette, Claudia Vaz, Bi, Minghong, Shi, Jianhua, Wang, Ke, Wang, Zhen, Yu, Xinmin, Dayen, Charles, Greillier, Laurent, Baraniskin, Alexander, Bischoff, Helge, Griesinger, Frank, Waller, Cornelius, Csoszi, Tibor, Laczo, Ibolya, Losonczy, Gyorgy, Tehenes, Sandor, Delmonte, Angelo, Follador, Alessandro, Batura-gabryel, Halina, Centkowski, Piotr, Danielewicz, Iwona, Kazarnowicz, Andrzej, Muntean, Alina Simona, Schenker, Michael, Adrian Udrea, Anghel, Ungureanu, Andrei, Karaseva, Nina, Kislov, Nikolay, Poddubskaya, Elena, Rozhkova, Irina, Solovyeva, Ekaterina, Zimina, Anastasia, Andric, Zoran, Kovcin, Vladimir, Petrovic, Marina, Radojevic, Zorica, Hong, Sookhee, Lee, Ki Hyeong, Shim, Byoung Yong, Alonso Garcia, Miriam, Calles Blanco, Antonio, Calderon, Vanesa Gutierrez, Massuti Sureda, Bartomeu, Paz-ares Rodriguez, Luis, Ho, Ching-liang, Lin, Sheng-hao, Liu, Chien-ying, Yang, Chih-hsin, Cicin, Irfan, Harputluoglu, Hakan, Selcuk Seber, Erdogan, Sezer, Ahmet, Adamchuk, Hryhoriy, Hotko, Yevhen
Format: Artikel
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:PURPOSE The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS Patients with SCLC and progression on or after first-line platinum-based chemotherapy were randomly assigned (1:1) to intravenous (IV) liposomal irinotecan (70 mg/m(2) every 2 weeks in a 6-week cycle) or IV topotecan (1.5 mg/m(2) daily for 5 consecutive days, every 3 weeks in a 6-week cycle). The primary end point was overall survival (OS). Key secondary end points included progression-free survival (PFS) and objective response rate (ORR). RESULTS Among 461 randomly assigned patients, 229 received liposomal irinotecan and 232 received topotecan. The median follow-up was 18.4 months. The median OS was 7.9 months with liposomal irinotecan versus 8.3 months with topotecan (hazard ratio [HR], 1.11 [95% CI, 0.90 to 1.37]; P = .31). The median PFS per blinded independent central review (BICR) was 4.0 months with liposomal irinotecan and 3.3 months with topotecan (HR, 0.96 [95% CI, 0.77 to 1.20]; nominal P = .71); ORR per BICR was 44.1% (95% CI, 37.6 to 50.8) and 21.6% (16.4 to 27.4), respectively. Overall, 42.0% and 83.4% of patients receiving liposomal irinotecan and topotecan, respectively, experienced grade >= 3 related treatment-emergent adverse events (TEAEs). The most common grade >= 3 related TEAEs were diarrhea (13.7%), neutropenia (8.0%), and decreased neutrophil count (4.4%) with liposomal irinotecan and neutropenia (51.6%), anemia (30.9%), and leukopenia (29.1%) with topotecan. CONCLUSION Liposomal irinotecan and topotecan demonstrated similar median OS and PFS in patients with relapsed SCLC. Although the primary end point of OS was not met, liposomal irinotecan demonstrated a higher ORR than topotecan. The safety profile of liposomal irinotecan was consistent with its known safety profile; no new safety concerns emerged.
DOI:10.1200/JCO.23.02110